新光药业
(300519)
| 流通市值：16.67亿 | | | 总市值：23.38亿 |
| 流通股本：1.14亿 | | | 总股本：1.60亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 93,250,095.71 | 267,659,927.41 | 216,211,460.22 | 146,210,038.02 |
| 营业收入 | 93,250,095.71 | 267,659,927.41 | 216,211,460.22 | 146,210,038.02 |
| 二、营业总成本 | 66,920,864.51 | 217,460,556.34 | 177,847,718.97 | 121,638,716.42 |
| 营业成本 | 58,941,107.85 | 177,116,596.25 | 140,364,926.08 | 96,499,935.86 |
| 税金及附加 | 1,654,805.85 | 4,503,032.44 | 3,511,891.38 | 2,328,183.57 |
| 销售费用 | 5,695,841.03 | 24,371,913.87 | 16,940,449.67 | 11,467,532.3 |
| 管理费用 | 4,619,139.89 | 17,512,159.92 | 11,724,886.84 | 8,242,833.93 |
| 研发费用 | 4,277,457.45 | 12,624,156.44 | 9,618,279.84 | 6,955,621.03 |
| 财务费用 | -8,267,487.56 | -18,667,302.58 | -4,312,714.84 | -3,855,390.27 |
| 其中:利息收入 | 8,271,108.09 | 18,680,938.96 | 4,323,126.6 | 3,863,048.33 |
| 加:投资收益 | 815,308 | 4,869,269.7 | 3,616,936.63 | 2,489,949.25 |
| 资产处置收益 | -3,722.27 | -67,847.01 | -67,847.01 | -67,847.01 |
| 资产减值损失(新) | -96,677.41 | -390,462.36 | -213,487.85 | -197,905.55 |
| 信用减值损失(新) | 216,044.91 | -109,696.09 | -390,429.15 | -1,983.45 |
| 其他收益 | 667,271.64 | 2,844,958.6 | 2,024,123.24 | 1,589,094.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 27,927,456.07 | 57,345,593.91 | 43,333,037.11 | 28,382,629.3 |
| 加:营业外收入 | 226,249.4 | 675,188 | 300,974 | 300,974 |
| 减:营业外支出 | 43.5 | 1,014,700 | 1,006,700 | 6,700 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 28,153,661.97 | 57,006,081.91 | 42,627,311.11 | 28,676,903.3 |
| 减:所得税费用 | 3,611,880.86 | 6,616,088.92 | 4,844,951.36 | 3,169,234.01 |
| 六、净利润 | 24,541,781.11 | 50,389,992.99 | 37,782,359.75 | 25,507,669.29 |
| 持续经营净利润 | 24,541,781.11 | 50,389,992.99 | 37,782,359.75 | 25,507,669.29 |
| 归属于母公司股东的净利润 | 24,541,781.11 | 50,389,992.99 | 37,782,359.75 | 25,507,669.29 |
| (一)基本每股收益 | 0.15 | 0.31 | 0.24 | 0.16 |
| (二)稀释每股收益 | 0.15 | 0.31 | 0.24 | 0.16 |
| 八、其他综合收益 | -66,771.95 | 21,068.42 | 16,614.39 | -231,393.57 |
| 归属于母公司股东的其他综合收益 | -66,771.95 | 21,068.42 | 16,614.39 | -231,393.57 |
| 九、综合收益总额 | 24,475,009.16 | 50,411,061.41 | 37,798,974.14 | 25,276,275.72 |
| 归属于母公司股东的综合收益总额 | 24,475,009.16 | 50,411,061.41 | 37,798,974.14 | 25,276,275.72 |
| 公告日期 | 2025-04-28 | 2025-04-21 | 2024-10-24 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |